Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients
These findings suggest that dapagliflozin may mitigate medullary hypoxia in CKD patients. BOLD-MRI could serve as a valuable biomarker for assessing renal functional reserve and predicting CKD progression. Further studies are warranted to confirm these effects and explore underlying molecular mechanisms.
Authors
- Giacomo Garibotto (ORCID: https://orcid.org/0000-0001-6432-2429)
- Emilio Venturelli
- Pasquale B. Esposito (ORCID: https://orcid.org/0000-0002-0834-5586)
- Francesca Cappadona (ORCID: https://orcid.org/0009-0008-8264-5318)
- Francesca Viazzi (ORCID: https://orcid.org/0000-0003-4219-7043)
- Lucia Macciò (ORCID: https://orcid.org/0009-0006-7018-6367)
- Maria Beatrice Damasio (ORCID: https://orcid.org/0000-0001-6737-1090)
- Elisa Russo (ORCID: https://orcid.org/0000-0003-1279-3178)
- Giulio Ferrazzi (ORCID: https://orcid.org/0000-0001-7449-4718)
- R Grillo (ORCID: https://orcid.org/0009-0009-4420-8691)
- Julie Di Vincenzo
Institutions
- Istituto Giannina Gaslini (IT)
- Ospedale Policlinico San Martino (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Philips (Italy) (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Kidney360
- Published
- 2025-11-12
- DOI
- https://doi.org/10.34067/kid.0000001015
- Citations
- 1
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.43